Cargando…
Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension
BACKGROUND: The aim of this study was to evaluate the stability and microbiological properties of a formulation of epoprostenol sodium with L-arginine and sucrose excipients (epoprostenol AS). METHODS: The stability of the reconstituted solutions after storage at 5°C and 25°C, diluted solutions (300...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459691/ https://www.ncbi.nlm.nih.gov/pubmed/23049244 http://dx.doi.org/10.2147/DDDT.S31628 |
_version_ | 1782244839713144832 |
---|---|
author | Lambert, Olivier Bandilla, Dirk |
author_facet | Lambert, Olivier Bandilla, Dirk |
author_sort | Lambert, Olivier |
collection | PubMed |
description | BACKGROUND: The aim of this study was to evaluate the stability and microbiological properties of a formulation of epoprostenol sodium with L-arginine and sucrose excipients (epoprostenol AS). METHODS: The stability of the reconstituted solutions after storage at 5°C and 25°C, diluted solutions (3000–60,000 ng/mL) at controlled room temperature, and diluted solutions (3000–60,000 ng/mL) stored at 5°C and then at room temperature were evaluated. Solutions were prepared using sterile water for injection or sterile saline (sodium chloride 0.9%) for injection. Shelf-life was assessed by determining potency over time relative to initial potency. In this context, potency is synonymous with content. The antimicrobial activity of reconstituted (100,000 ng/mL for 0.5 mg vial, 300,000 ng/mL for 1.5 mg vial) and diluted (3000 ng/mL) epoprostenol AS was measured using an antimicrobial effectiveness test after inoculation with six species of bacteria, yeast, and mold. RESULTS: Reconstituted epoprostenol AS was stable for up to one day’s storage at 25°C or 7 days’ storage at 5°C. Epoprostenol AS was stable for up to 72 hours when diluted, depending on temperature and concentration. The maximum shelf-life of the diluted solution if the reconstituted solution had been stored for up to one day at room temperature or up to 7 days at 5°C, was between 24 and 72 hours, depending on concentration. Following storage of diluted solutions at 5°C for up to 8 days, maximum shelf-life was between one and 2 days, depending on temperature and concentration. Potency was not dependent on diluents. Preservative testing confirmed no microbial growth for any of six organisms tested for at least 14 days at 5°C or 25°C for the reconstituted solution and for at least 16 days at 5°C followed by one day at 25°C for the diluted solutions. CONCLUSION: Epoprostenol AS has favorable thermal stability and does not support the growth of any micro-organism tested for up to 17 days. This extended stability under ambient conditions has the potential to improve convenience further for patients. |
format | Online Article Text |
id | pubmed-3459691 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-34596912012-10-03 Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension Lambert, Olivier Bandilla, Dirk Drug Des Devel Ther Original Research BACKGROUND: The aim of this study was to evaluate the stability and microbiological properties of a formulation of epoprostenol sodium with L-arginine and sucrose excipients (epoprostenol AS). METHODS: The stability of the reconstituted solutions after storage at 5°C and 25°C, diluted solutions (3000–60,000 ng/mL) at controlled room temperature, and diluted solutions (3000–60,000 ng/mL) stored at 5°C and then at room temperature were evaluated. Solutions were prepared using sterile water for injection or sterile saline (sodium chloride 0.9%) for injection. Shelf-life was assessed by determining potency over time relative to initial potency. In this context, potency is synonymous with content. The antimicrobial activity of reconstituted (100,000 ng/mL for 0.5 mg vial, 300,000 ng/mL for 1.5 mg vial) and diluted (3000 ng/mL) epoprostenol AS was measured using an antimicrobial effectiveness test after inoculation with six species of bacteria, yeast, and mold. RESULTS: Reconstituted epoprostenol AS was stable for up to one day’s storage at 25°C or 7 days’ storage at 5°C. Epoprostenol AS was stable for up to 72 hours when diluted, depending on temperature and concentration. The maximum shelf-life of the diluted solution if the reconstituted solution had been stored for up to one day at room temperature or up to 7 days at 5°C, was between 24 and 72 hours, depending on concentration. Following storage of diluted solutions at 5°C for up to 8 days, maximum shelf-life was between one and 2 days, depending on temperature and concentration. Potency was not dependent on diluents. Preservative testing confirmed no microbial growth for any of six organisms tested for at least 14 days at 5°C or 25°C for the reconstituted solution and for at least 16 days at 5°C followed by one day at 25°C for the diluted solutions. CONCLUSION: Epoprostenol AS has favorable thermal stability and does not support the growth of any micro-organism tested for up to 17 days. This extended stability under ambient conditions has the potential to improve convenience further for patients. Dove Medical Press 2012-09-17 /pmc/articles/PMC3459691/ /pubmed/23049244 http://dx.doi.org/10.2147/DDDT.S31628 Text en © 2012 Lambert and Bandilla, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Lambert, Olivier Bandilla, Dirk Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension |
title | Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension |
title_full | Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension |
title_fullStr | Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension |
title_full_unstemmed | Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension |
title_short | Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension |
title_sort | stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459691/ https://www.ncbi.nlm.nih.gov/pubmed/23049244 http://dx.doi.org/10.2147/DDDT.S31628 |
work_keys_str_mv | AT lambertolivier stabilityandpreservationofanewformulationofepoprostenolsodiumfortreatmentofpulmonaryarterialhypertension AT bandilladirk stabilityandpreservationofanewformulationofepoprostenolsodiumfortreatmentofpulmonaryarterialhypertension |